[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mastectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mastectomy":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,33,0,25,[9,45,82,104,135,166,197,220,240,259,300,326,355,367,387,410,435,461,499,523,553,575,613,635,659],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100054318","biological-and-clinical-underpinnings-of-postoperative-pain---mastectomy-100054318",false,"NCT07271589","Biological and Clinical Underpinnings of Postoperative Pain - Mastectomy","Biological and Clinical Underpinnings of Postoperative Pain - Mastectomy (BAC-UPP 1 Study)","BAC-UPP 1","Inclusion Criteria:\n\n* Participants scheduled for breast surgery\u002Fmastectomy ; 2) age between 18-65; 3) understanding of verbal and written English.\n\nExclusion Criteria:\n\n* 1\\) concurrent medical conditions that could confound the interpretation of the data; 2) HIV positive diagnosis; 3) cardiovascular or pulmonary disease; 4) systemic rheumatoid disease; 5) uncontrolled hypertension (i.e. SBP\u002FDBP of \\> 150\u002F95); 6) current illness accompanied by fever (body temperature \\>38 °C); 7) any other chronic pain condition; 8) conditions resulting in altered nerve sensation; 9) hospitalization due to psychiatric illness within the last 6 months; 10) poorly controlled diabetes; 11) history of stroke; 12) history of seizures; 13) circulatory disorders such AS Raynauds' disease 14) history of drug or alcohol abuse.","ALL","18 Years","89 Years",{"count":22,"type":23},86,"ESTIMATED","OBSERVATIONAL","Persistent pain after mastectomy remains a significant clinical challenge that can delay recovery, reduce quality of life, and increase long-term healthcare burden. The goal of this study is to gain a deeper understanding of the biological and clinical factors that influence pain severity after mastectomy and contribute to the transition from acute to chronic postoperative pain. Guided by a biopsychosocial framework, this research will address the following aims:\n\n1. We will use standardized experimental pain testing before surgery to evaluate how patients respond to different types of controlled sensory stimuli. These responses may help predict who is more likely to experience severe or prolonged pain after surgery.\n2. We will analyze blood samples collected before and after surgery to measure markers of inflammation and other biological responses. These data will help us explore how the body's immune and hormonal systems relate to pain severity in both the short- and longer-term recovery phases.\n3. We will assess psychological and clinical factors, such as emotional health, coping style, household income, and life stressors, to understand how they contribute to patients' pain experiences throughout recovery.\n4. We will examine whether routinely collected demographic and clinical characteristics can help identify patients at greater risk of experiencing higher levels of pain after surgery. This approach will allow us to better understand which patients may benefit from more tailored perioperative pain management strategies.",[27],"Mastectomy",[27,29,30,31,32],"breast surgery","nociception","acute pain","chronic pain","NOT_YET_RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":23},"2026-09-01",{"date":41,"type":23},"2028-08-31",{"name":43,"class":44},"University of Alabama at Birmingham","OTHER",{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100641523","timing-of-serratus-anterior-plane-block-in-mastectomy-surgery-100641523","NCT07661212","Timing of Serratus Anterior Plane Block in Mastectomy Surgery","The Effect of Serratus Anterior Plane Block Timing on Postoperative Quality of Recovery, Postoperative Pain, and Inflammatory Response in Elective Unilateral Mastectomy Surgery: A Prospective Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Female patients aged 18 years or older\n* Scheduled for elective unilateral mastectomy surgery\n* Planned to undergo surgery under general anesthesia\n* American Society of Anesthesiologists physical status I-III\n* Willing and able to participate in the study\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* Known allergy to local anesthetics planned for use in the study\n* Chronic opioid use\n* Current steroid or immunosuppressive therapy\n* Presence of chronic inflammatory disease\n* Surgical duration shorter than 30 minutes\n* Active infection\n* Coagulopathy\n* Infection at the planned block site\n* Pregnancy or lactation\n* Advanced hepatic failure or advanced renal failure\n* Reoperation due to recurrent disease\n* Inability to communicate adequately or to provide reliable pain scores\n* Psychiatric or neurological condition limiting reliable completion of the QoR-15 questionnaire or Numeric Rating Scale assessments","FEMALE",{"count":54,"type":23},80,"INTERVENTIONAL",[57],"NA","Postoperative pain following mastectomy may adversely affect early mobilization, patient comfort, and overall quality of recovery. Serratus anterior plane block is an ultrasound-guided regional anesthesia technique that provides analgesia to the anterolateral thoracic wall and is increasingly used as part of multimodal analgesia for breast surgery. Although the analgesic efficacy of serratus anterior plane block has been investigated in breast surgery, the clinical impact of the timing of block administration remains insufficiently defined.\n\nThis prospective, randomized, controlled, patient and assessor blinded clinical trial will compare two different timings of ultrasound-guided serratus anterior plane block in adult female patients undergoing elective unilateral mastectomy under general anesthesia. Participants will be randomized to receive serratus anterior plane block either after induction of general anesthesia and before surgical incision, or after completion of surgery and before extubation. In both groups, the block will be performed under ultrasound guidance using 25 mL of 0.25% bupivacaine.\n\nThe primary outcome is postoperative quality of recovery at 24 hours, assessed using the Quality of Recovery-15 questionnaire. Secondary outcomes include postoperative pain scores at predefined time points during the first 24 postoperative hours, intraoperative remifentanil consumption, postoperative opioid and non-opioid analgesic requirements, time to first analgesic requirement, postoperative nausea and vomiting, length of hospital stay, complications, inflammatory response markers including CRP and neutrophil-to-lymphocyte ratio, and intraoperative hemodynamic variables.\n\nThe study is planned to enroll 80 participants at a single tertiary training and research hospital. The findings are expected to clarify whether preincisional administration of serratus anterior plane block provides superior postoperative recovery, analgesic efficacy, and modulation of inflammatory response compared with administration at the end of surgery.",[60,61,62,27],"Quality of Recovery After Mastectomy","Serratus Anterior Plane Block","Postoperative Pain",[61,62,27,64,65,66,67,68,69,70,71],"Regional Anesthesia","Pain Management","Bupivacaine","Quality of Recovery","CRP","Neutrophil-Lymphocyte Ratio","Inflammation","Breast Surgery","2026-06-18",{"date":74,"type":37},"2026-06-22",{"date":39,"type":23},{"date":77,"type":23},"2027-10-01",{"name":79,"class":80},"Bakirkoy Dr. Sadi Konuk Research and Training Hospital","OTHER_GOV",1,{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":55,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":81},"100430932","a-comparative-analysis-of-revolve-lipografter-and-viality-in-autologous-fat-grafting-during-breast-surgery-100430932","NCT04891510","A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery","Inclusion Criteria:\n\n* Female;\n* Documented history of previous breast surgery (either complete or partial mastectomy);\n* Available harvest sites for fat grafting as documented by plastic surgeon;\n* BMI \\> 20;\n* Anticipated harvested fat volume \\> 50cc;\n* Competency and willingness to provide consent\n\nExclusion Criteria:\n\n* Suspected or known to be pregnant",{"count":89,"type":23},135,[57],"The purpose of this study is to learn whether there is a superior fat processing method in terms of graft retention in breast reconstruction after mastectomy.",[27,93,94],"Mammaplasty","Breast Reconstruction","RECRUITING","2026-06-17",{"date":74,"type":37},{"date":99,"type":37},"2021-05-19",{"date":101,"type":23},"2028-06-01",{"name":103,"class":44},"Weill Medical College of Cornell University",{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":112,"sex":18,"minAge":113,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":55,"phases":116,"briefSummary":117,"conditions":118,"keywords":121,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":81},"100604257","evaluating-the-efficacy-of-force-modulating-tissue-bridge-device-in-preventing-hypertrophic-scars-following-gender-affirming-mastectomy-100604257","NCT07147166","Evaluating the Efficacy of Force Modulating Tissue Bridge Device in Preventing Hypertrophic Scars Following Gender-Affirming Mastectomy","Evaluating the Efficacy of Force Modulating Tissue Bridge Device in Preventing Hypertrophic Scars Following Gender-Affirming Mastectomy: A Randomized Self-Controlled Trial","FMTB Brij","Inclusion Criteria:\n\n1. Age ≥ 19\n2. Undergoing double incision gender affirming mastectomy\n3. Ability to adhere to Brijjit therapy after surgery\n4. Willing to return for follow-up visits and undergo study evaluations\n\nExclusion Criteria:\n\n1. History of keloid formation\n2. Radiation therapy history\n3. Prior surgeries of the chest or breast\n4. History or use following prescription medications: 1) accutane within the past year. 2) chronic systemic steroids\n5. Active smoker\n6. Disorder known to negatively affect wound healing (autoimmune, connective tissue, uncontrolled diabetes)\n7. Any other condition determined by PI to preclude subject from joining study",true,"19 Years",{"count":115,"type":23},78,[57],"The goal of this randomized, prospective, interventional clinical trial is to evaluate the use of Brijjit® in reducing the incidence of hypertrophic scarring in individuals undergoing gender-affirming bilateral double incision mastectomies at a single-institution, single-surgeon site (Esther A. Kim, MD). Patients will serve as a self-control (one side of the chest receives intervention, the other serves as a control). Primary endpoints include scar appearance and quality. Secondary endpoints include patient perception of the scar using the Patient and Observer Scar Assessment Scale (POSAS).\n\nParticipants will be taught how to apply Brijjit® at home if any units fall off before 6 weeks postop.",[119,27,120],"Gender Dysphoria","Hypertrophic Scar",[122,123,124,125],"Gender-affirming","Gender-affirming care","Gender-affirming mastectomy","Hypertrophic scarring","2026-06-02",{"date":128,"type":37},"2026-06-04",{"date":130,"type":37},"2025-02-03",{"date":132,"type":23},"2032-06-01",{"name":134,"class":44},"University of California, San Francisco",{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":55,"phases":146,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":81},"100634221","comparison-of-serratus-posterior-superior-intercostal-plane-block-and-rhomboid-intercostal-block-in-patients-undergoing-breast-cancer-surgery-100634221","NCT07536867","Comparison of Serratus Posterior Superior Intercostal Plane Block and Rhomboid Intercostal Block in Patients Undergoing Breast Cancer Surgery","Comparison of Serratus Posterior Superior Intercostal Plane Block and Rhomboid Intercostal Block for Postoperative Analgesia Following Breast Cancer Surgery With Axillary Lymph Node Dissection: A Randomized Controlled Trial","SPSIP-RIB","Inclusion Criteria:\n\n* Female patients aged 18-65 years\n* ASA physical status I-III\n* Scheduled for elective breast cancer surgery with axillary lymph node dissection\n* Body mass index (BMI) between 18 and 35 kg\u002Fm²\n* Ability to understand and use the patient-controlled analgesia (PCA) device\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Refusal to participate\n* Allergy to local anesthetics\n* Infection at the injection site\n* Coagulopathy or ongoing anticoagulant therapy\n* Chronic opioid use or opioid dependence\n* Severe hepatic or renal insufficiency\n* Pregnancy or breastfeeding\n* Cognitive impairment or inability to communicate pain scores\n* Body mass index (BMI) \\\u003C18 or \\>35 kg\u002Fm²","65 Years",{"count":145,"type":23},60,[57],"This randomized clinical trial aims to evaluate and compare the analgesic efficacy of the Serratus Posterior Superior Intercostal Plane (SPSIP) and Rhomboid Intercostal Block in patients undergoing Breast Cancer Surgery With Axillary Lymph Node Dissection. The primary outcome is Visual Analog Scale (VAS) during the first 24 hours after surgery. Secondary outcomes include total opioid consumption, requirement for rescue analgesia, block performance time, block-related and systemic side effects (hematoma, pneumothorax, local anesthetic toxicity, vascular puncture, infection), Patient satisfaction assessed using a Likert scale, quality of recovery assessed using the QoR-15 questionnaire.",[149,150,62,27],"Breast Cancer","Lymph Node Dissection",[152,153,154,155,156],"SPSIP","rhomboid intercostal block","regional anesthesia","axillary dissection","serratus posterior superior intercostal plane block","2026-05-07",{"date":159,"type":37},"2026-05-11",{"date":161,"type":23},"2026-08-30",{"date":163,"type":23},"2027-09-30",{"name":165,"class":44},"Antalya City Hospital",{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":112,"sex":18,"minAge":174,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":55,"phases":178,"briefSummary":179,"conditions":180,"keywords":185,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":81},"100521762","the-role-of-amnion-membrane-allografts-in-nipple-preservation-100521762","NCT06073808","The Role of Amnion Membrane Allografts in Nipple Preservation","The Role of Amnion Membrane Allografts in Nipple Preservation After Nipple Sparing Mastectomy: A Double-Blinded Randomized Controlled Trial","AmnioFix","Inclusion Criteria:\n\n* Biologically female with documented diagnosis of gender dysphoria, desire to undergo gender affirming surgery (female-to-male) NSM, and age 15 years of age or older.\n* Biological female, age 18 to 75 years old, who desire to undergo bilateral prophylactic NSM for nonmalignant breast conditions or to reduce the risk of breast cancer.\n\nExclusion Criteria:\n\n* Current steroid use\n* Known connective tissue disorder\n* Known neuropathy\n* Known history of breast cancer\n* History of breast radiotherapy\n* Pregnant or nursing","15 Years","75 Years",{"count":177,"type":23},30,[57],"The overall objective of this proposal is to conduct a randomized-controlled study to determine whether treatment with dehydrated human amnion\u002Fchorion membrane (dHACMs) allografts can improve NAC viability in patients undergoing nipple sparing mastectomy (NSM). dHACM allografts are commercially available tissue membranes with biocompatible extracellular matrix and growth factors that have been shown to improve wound healing in patients with chronic and lower extremity wounds. To date, no study has evaluated the impact of dHACMs on NAC preservation following NSM. Investigators hypothesize that subareolar surgical implantation of dHACM allografts at time of NSM will reduce NAC necrosis and improve viability.",[27,181,182,183,184],"Gender Affirmation Surgery","Nipple Sparing Mastectomy","Prophylactic Mastectomy","Benign Breast Condition",[186,187],"nipple sparing mastectomy","gender affirming surgery","2026-04-24",{"date":190,"type":37},"2026-04-30",{"date":192,"type":23},"2026-06-01",{"date":194,"type":23},"2026-09",{"name":196,"class":44},"Stanford University",{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":55,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":81},"100545466","a-bionic-breast-project-using-neuroprosthesis-to-reduce-chronic-pain-after-mastectomy-100545466","NCT06382272","A Bionic Breast Project Using Neuroprosthesis to Reduce Chronic Pain After Mastectomy","Bionic Breast Project: A Neuroprosthesis to Restore Touch Sensation and Reduce Chronic Pain After Mastectomy","Inclusion criteria:\n\n* 18 years of age or older\n* Scheduled for bilateral mastectomy with two-stage (tissue expander) reconstruction at UCM\n* Bilateral mastectomy for unilateral in situ or T1to T2, clinically, N0 (no lymph node involvement) breast cancer or breast cancer risk reduction due to known elevated breast cancer risk. (Note - 19-34% of women choosing mastectomy for small unilateral breast cancer elect bilateral mastectomy.)40 We will enroll from this cohort.\n* Agrees to have breast tissue expander removed within 12-20 weeks of implantation.\n* Has access to a cell phone and willing to provide the research interviewer with the cell phone number\n* Agrees to receive text messages from the study\n* Able to speak and understand English or Spanish\n* Able to participate in the informed consent process\n\nExclusion criteria:\n\n* Requires adjuvant chemotherapy\n* Single stage mastectomy and reconstruction procedure\n* Clinical evidence of bilateral breast cancer\n* Clinical evidence of lymph node involvement\n* Prior history of mastectomy or other major breast surgery\n* Prior history of radiation to the chest area (e.g., mantle radiation for Hodgkin's disease)\n* Prior history of injury (e.g., trauma, surgery, burn) that the participant perceives to have had an effect on the sensation of the breast\n* Pregnant or intending to become pregnant during the study period\n* Pacemaker, defibrillator or other implanted electrical stimulation device that may be affected by the implanted electrodes\n* Complex regional pain syndrome or other pain syndromes or a history of a neurologic condition like multiple sclerosis, degenerative neurological disease, cognitive impairment or dementia\n* Uncontrolled diabetes\n* History of poor wound healing or chronic skin ulcerations\n* History of uncontrolled infection or active infection at time of consent\n* Expectation that MRI will be required while the devices are implanted\n* Inability or unwillingness to follow verbal instructions and comply with study procedures\n* Untreated or poorly managed physical or mental health condition that may pose additional risk according to clinical judgment of the patient's breast surgeon or surgeons\n* Unwillingness to undergo psychological evaluation to determine study eligibility, if requested or required by surgeons or investigators",{"count":205,"type":23},8,[57],"This trial seeks to establish whether or not touch sensation can be restored to the breast via neural stimulation. Data will also be obtained to inform future feasibility (including safety), efficacy, and acceptability trials.",[27,209,210],"Breast","Chronic Pain","2026-04-22",{"date":213,"type":37},"2026-04-27",{"date":215,"type":37},"2025-05-14",{"date":217,"type":23},"2028-01-31",{"name":219,"class":44},"University of Chicago",{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":55,"phases":228,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":81},"100570801","interactive-design-of-patient-specific-molds-for-tissue-shaping-100570801","NCT06711965","Interactive Design of Patient-Specific Molds for Tissue Shaping","Inclusion Criteria:\n\n1. Patients 18 years of age or older\n2. Patients who are willing and able to provide informed consent\n3. Patients who are scheduled to undergo breast reconstruction with free flap (Deep Interior Epigastric Artery Perforator (DIEP) flap or Transverse Rectus Abdominis Myocutaneous (TRAM) flap)\n\nExclusion Criteria:\n\n1. Patients whose surgical plan includes the use of stacked flaps (DIEP + other free flap, usually from the thigh or buttock)\n2. Patients whose surgical plan includes the use of DIEP flap with vascularized lymph node transfer\n3. Patients undergoing neoadjuvant radiation",{"count":227,"type":23},160,[57],"The goal of this study is to develop clinical decision-support algorithms for designing participants-specific breast molds for tissue shaping. Autologous breast reconstruction is an important part of breast cancer rehabilitation for many participants. Our goal is to increase the efficiency of autologous breast reconstruction by helping the surgeon design participants-specific molds for shaping tissue into an acceptable breast form.",[27],"2026-04-13",{"date":233,"type":37},"2026-04-16",{"date":235,"type":37},"2025-07-17",{"date":237,"type":23},"2030-08-01",{"name":239,"class":44},"M.D. Anderson Cancer Center",{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":143,"enrollmentInfo":247,"targetDuration":4,"studyType":55,"phases":249,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":258,"locationsCount":81},"100514197","assessment-of-the-interi-manifold-in-implant-based-breast-reconstruction-100514197","NCT05975359","Assessment of the Interi Manifold in Implant-Based Breast Reconstruction","A Pilot Study of the Interi Manifold With Traditional Surgical Drains in Implant-Based Breast Reconstruction","Inclusion Criteria:\n\n1. Breast cancer diagnosis (any form) or Genetic mutation with presence of breast mass.\n2. Indication for bilateral mastectomy\n3. Plan for immediate, implant-based pre-pectoral breast reconstruction using an acellular dermal matrix\n4. Age 18 - 65\n5. Female Sex\n6. Ability to understand and the willingness to personally sign the written IRB-approved informed consent document (English language).\n\nExclusion Criteria:\n\n1. Have a prior history of radiation to the breast or planned radiotherapy to the breast within the first year post-operatively.\n2. Are enrolled in another study that requires the concomitant use of any investigational product during the study period that the Principal Investigator believes will interfere with study endpoints.\n3. Have received oncologic chemotherapy within the past 21 days or planned within the time fame of the study intervention. Have received antiplatelet therapy (other than aspirin) and\u002F or other anticoagulation therapy in the past 60 days.\n4. Are a smoker or use illicit drugs.\n5. Any prior allergic reaction to Teflon.\n6. Are pregnant or nursing.\n7. Are undergoing a delayed reconstruction following mastectomy.\n8. HIV infection, active UTI infection, or other active infection.\n9. Those requiring more than one Manifold for fluid removal per breast will be excluded.",{"count":248,"type":23},20,[57],"Patients with breast cancer that elect to undergo implant-based breast reconstruction (IBBR) often require the placement of a surgical drain. Surgical drains are used to manage dead space and prevent seroma formation or accumulation of fluid within the surgical field postoperatively. The most frequently used drain is a Jackson-Pratt (JP) drain, which is limited by poor surgical site coverage and low capacity, leading to inconsistent suction and prolonged time that a drain is left in place. The Interi Drain system is a novel, multi-branched manifold with a proprietary suction system that provides consistent suction and addresses many of the shortcoming of JP drains. The purpose of this study is to compare the Interi system to standard JP drains across outcomes including number of surgical drain sites, complication rates, time to drain removal, time to initiate tissue expansion, total fluid volume drained, and patient satisfaction.",[27,252],"Implant Based Breast Reconstruction","2026-04-09",{"date":231,"type":37},{"date":256,"type":37},"2023-10-05",{"date":194,"type":23},{"name":196,"class":44},{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":175,"enrollmentInfo":267,"targetDuration":4,"studyType":55,"phases":269,"briefSummary":270,"conditions":271,"keywords":274,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":296,"leadSponsor":298,"locationsCount":81},"100632208","same-day-awake-mastectomy-with-immediate-breast-reconstruction-for-patients-with-breast-cancer-100632208","NCT07510698","Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer","Evaluation of Safety, Quality of Life, Cost and Environmental Impact of Day Surgery in Mastectomy and Prepectoral Reconstruction - Awake MAstectomy in Day Surgery With Immediate Prepectoral Implant Reconstruction and Muscle Sparing","AMADeuS","\\*\\*Inclusion Criteria:\\*\\*\n\n* Biologically female participants aged 18 to 75 years\n* Oncologic or prophylactic indication for nipple-sparing mastectomy or skin-sparing mastectomy with immediate prepectoral reconstruction using a definitive implant or tissue expander, including early breast cancer or a high-risk genetic condition such as BRCA\n* Eligible for prepectoral reconstruction based on clinico-anatomic criteria, including adequate skin flap thickness, no relevant vascular compromise, body mass index less than 35, and no severe prior chest radiotherapy\n* American Society of Anesthesiologists (ASA) class I to III\n* Eligible for day surgery, defined by home autonomy, caregiver availability during the first 24 hours after surgery, and distance from the hospital compatible with home management\n* Able and willing to complete telemedicine follow-up, including completion of protocol-required patient-reported outcome measures\n* Written informed consent provided\n\n\\*\\*Exclusion Criteria:\\*\\*\n\n* Chronic opioid use or treatment for pre-existing chronic pain that could interfere with assessment of the primary postoperative pain endpoint\n* Contraindications to locoregional anesthesia techniques or to the awake\u002Fmonitored anesthesia care protocol, including allergy to local anesthetics, coagulation disorders, or inability to cooperate during surgery\n* Body mass index 35 or greater, or anatomic conditions contraindicating prepectoral reconstruction\n* Previous high-dose chest radiotherapy with significant tissue compromise\n* Pregnancy or breastfeeding\n* Inability to guarantee planned follow-up or lack of adequate home support\n* Psychiatric or cognitive conditions preventing correct completion of patient-reported outcome measures",{"count":268,"type":23},100,[57],"The goal of this clinical trial is to learn if the AMADeuS care pathway is as safe as usual hospital care and works as well for pain control in women having mastectomy with immediate prepectoral breast reconstruction. The study will also look at quality of life, satisfaction with care, hospital resource use, and environmental impact.\n\nThe main questions it aims to answer are:\n\n1. Does the AMADeuS pathway control pain during the first 48 hours after surgery as well as usual hospital care?\n2. Is the AMADeuS pathway as safe as usual hospital care during the first 30 days after surgery?\n3. Can the AMADeuS pathway improve recovery, reduce hospital stay and hospital visits, and lower the environmental impact of care?\n\nResearchers will compare the AMADeuS pathway with usual hospital care. In the AMADeuS pathway, participants will have awake surgery with monitored anesthesia care, same-day discharge when safe, and follow-up that includes telemedicine. In the usual care group, participants will receive the hospital's standard perioperative care, which usually includes admission to the ward and follow-up visits at the hospital.\n\nParticipants may be women 18 to 75 years old who need nipple-sparing or skin-sparing mastectomy with immediate prepectoral reconstruction for early breast cancer or to lower future breast cancer risk. Participants must be suitable for day surgery and telemedicine follow-up. This includes having home support during the first 24 hours after surgery and living close enough to the hospital for safe discharge.\n\nParticipants will:\n\n* be assigned by chance to the AMADeuS pathway or to usual hospital care have mastectomy with immediate prepectoral reconstruction report their pain during the first 48 hours after surgery\n* be checked for medical problems during the first 30 days after surgery complete questionnaires about quality of life, symptoms, and satisfaction with care during follow-up\n* have follow-up visits either through telemedicine and planned local care support or through standard hospital follow-up, depending on the group they are assigned to",[149,27,272,273],"Prepectoral Breast Reconstruction","ERAS Programmes",[275,276,277,278,186,279,280,281,282,283,284,285,286,287,288,289,290,291],"Amadeus","Breast cancer","Bugs","mastectomy","skin sparing mastectomy","immediate breast reconstruction","prepectoral breast reconstruction","Carbon footprint","ERAS","Sustainable surgery","Patient-reported outcomes","Postoperative pain","Telemedicine","Same-day discharge","Day surgery","Awake breast surgery","Monitored anesthesia care","2026-04-01",{"date":294,"type":37},"2026-04-03",{"date":292,"type":37},{"date":297,"type":23},"2028-04-01",{"name":299,"class":44},"University of Rome Tor Vergata",{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":175,"enrollmentInfo":307,"targetDuration":4,"studyType":55,"phases":309,"briefSummary":310,"conditions":311,"keywords":314,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":81},"100632175","investigation-of-the-effects-of-serratus-posterior-superior-intercostal-plane-block-and-serratus-anterior-plane-block-on-perioperative-analgesia-management-in-patients-scheduled-for-mastectomy-100632175","NCT07510269","Investigation of the Effects of Serratus Posterior Superior Intercostal Plane Block and Serratus Anterior Plane Block on Perioperative Analgesia Management in Patients Scheduled for Mastectomy","Mastektomi Planlanan Hastalarda Serratus Posterior Superior İnterkostal Plan Bloğu Ile Serratus Anterior Plan Bloğunun Peroperatif Analjezi Yönetimi Üzerine Etkilerinin Araştırılması","Inclusion Criteria:\n\n* Female patients aged between 18 and 75 years\n* Patients scheduled for elective mastectomy surgery\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Patients who provide written informed consent\n\nExclusion Criteria:\n\n* Patients who refuse to participate in the study\n* Patients with American Society of Anesthesiologists (ASA) physical status IV or V\n* Patients receiving anticoagulant therapy or with suspected coagulopathy\n* Patients with known allergy to local anesthetic agents\n* Infection at the site of block application\n* Pregnant patients or those with suspected pregnancy\n* Patients with severe neurological or psychiatric disorders\n* Patients with severe cardiovascular disease\n* Patients with chronic opioid use\n* Patients with hepatic failure or renal failure (glomerular filtration rate \\\u003C15 mL\u002Fmin\u002F1.73 m²)",{"count":308,"type":23},66,[57],"This study aims to evaluate and compare the analgesic efficacy of two ultrasound-guided regional anesthesia techniques, the serratus anterior plane (SAP) block and the serratus posterior superior intercostal plane (SPSIP) block, in patients undergoing elective mastectomy surgery. Postoperative pain following mastectomy is a common and significant clinical problem that negatively affects patient comfort, delays mobilization, and may prolong hospital stay. Although systemic analgesics are commonly used, they are associated with adverse effects such as sedation, constipation, and potential dependency.\n\nIn this randomized clinical study, female patients aged 18-75 years with ASA physical status I-III scheduled for elective mastectomy will be included after obtaining informed consent. Patients will be allocated into two groups to receive either SAP block or SPSIP block under ultrasound guidance prior to surgery. Standardized general anesthesia and perioperative analgesia protocols will be applied to all patients.\n\nThe primary objective is to compare postoperative pain scores between the two groups using the Numeric Rating Scale (NRS). Secondary outcomes include time to first analgesic requirement, total analgesic consumption, intraoperative opioid use, and hemodynamic parameters. By comparing these two interfascial plane blocks, this study aims to identify a more effective analgesic technique that improves postoperative pain control, enhances patient comfort, and facilitates early mobilization following mastectomy.",[62,312,27,313],"Nerve Block","Patient Outcome Assessment",[315,61,316,317],"Serratus Posterior Superior Intercostal Plane Block","Multimodal Analgesia","Mastectomy Surgery","2026-03-29",{"date":294,"type":37},{"date":321,"type":37},"2025-10-15",{"date":323,"type":23},"2026-10-15",{"name":325,"class":44},"Uludag University",{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":55,"phases":335,"briefSummary":337,"conditions":338,"keywords":341,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":354},"100444813","phase-3-long-term-outcomes-of-lidocaine-infusions-for-post-operative-pain-lolipop-trial-100444813","NCT05072314","Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial","LOLIPOP","Inclusion Criteria:\n\n* Consenting adult female patients (≥18 years) undergoing mastectomy (unilateral or bilateral) or breast conserving surgery (unilateral or bilateral) for the primary excision of confirmed or suspected primary breast cancer under general anaesthesia (including those with simultaneous insertion of tissue expanders or implants)\\*. \\* this specifically excludes patients undergoing surgery for locoregional recurrence\n* American Society of Anaesthesiologist (ASA) physical scale 1-3\n\nExclusion Criteria:\n\n* Mastectomy or breast conserving surgery with add on procedures e.g laparoscopic salpingectomy\n* Where surgery is being performed for locoregional recurrence of breast cancer\n* Pre-existing pain at site of surgery, axilla, ipsilateral side of chest wall or the ipsilateral upper arm (at diagnosis prior to any tumor locating procedures)\n* Re-excision procedures where the margins at the index surgery have been deemed insufficient\n* When immediate autologous reconstruction surgery is planned\n* Where delayed autologous reconstruction surgery on the operative breast within one year is planned\n* Planned use of regional analgesia infusions\n* Impaired cognition\n* Pregnant or lactating females\n* Transgender patients\n* Known metastatic disease\n* History of anaphylaxis, sensitivity or known contraindication to lidocaine (or other amide local anaesthetic agents e.g. other amide local anaesthetic agents: ropivacaine, bupivacaine, mepivacaine, prilocaine, etidocaine), including patients with porphyria or methaemoglobinaemia\n* History of epilepsy\n* Baseline heart rate \\< 50 bpm or systolic blood pressure \\< 100mmHg.\n* Acute coronary event in the last three months\n* Cardiac conduction abnormalities, including; Atrial fibrillation, Heart block (all degrees), Bundle Branch Block or Fascicular block, Prolonged QT interval, Wolf Parkinson White syndrome, channelopathy such as Brugada syndrome. A preoperative Electrocardiogram (ECG) is not mandatory, unless clinically indicated\n* Abnormal serum potassium concentration (based upon site laboratory reference ranges)\n* Active liver disease e.g. viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, haemochromatosis, other rarer causes)\n* Medications within the last 7 days which are known \u002F suspected to slow lidocaine metabolism (amiodarone, beta blockers, cimetidine, fluoroquinolones, fluvoxamine, imidazoles, macrolides, verapamil, HIV drugs)\n* Cardiac Failure (any documented heart failure at peroperative assessment or GP records)\n* Severe Renal Failure (Creatinine Clearance of less than 30ml\u002Fmin or dialysis dependent)\n* Co-administration of lidocaine within 24 hours prior to surgery for other reasons (e.g. lidocaine patches",{"count":334,"type":23},4300,[336],"PHASE3","The LOLIPOP Trial is a large (n=4,300 patients) pragmatic, international, multicentre, prospective, randomised, double blind, placebo-controlled, parallel assessment, safety and effectiveness superiority study.",[149,339,340,27],"Breast Cancer Female","Breast Conserving Surgery",[342,343,344],"Anaesthesia","Local Anaesthesia","Chronic Post Surgical Pain","2026-03-22",{"date":347,"type":37},"2026-03-25",{"date":349,"type":37},"2022-07-27",{"date":351,"type":23},"2028-07",{"name":353,"class":44},"Monash University",47,{"id":356,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":357,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":358,"keywords":359,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":366,"locationsCount":4},"100613822",{"count":22,"type":23},[27],[27,29,30,31,32],"2026-03-11",{"date":362,"type":37},"2026-03-16",{"date":364,"type":23},"2026-05-01",{"date":41,"type":23},{"name":43,"class":44},{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":52,"minAge":373,"maxAge":143,"enrollmentInfo":374,"targetDuration":4,"studyType":55,"phases":375,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":81},"100627314","selected-exercise-program-on-upper-cross-syndrome-post-unilateral-mastectomy-100627314","NCT07447024","Selected Exercise Program on Upper Cross Syndrome Post-unilateral Mastectomy","Inclusion Criteria:\n\n* The subject selection will be according to the following criteria:\n* Age range between 45-65years.\n* Females only will participate in the study.\n* All patients have upper cross syndrome post-unilateral modified radical mastectomy\n* All patients relatives enrolled the study will have their informed consent.\n\nExclusion Criteria:\n\n* Age more than 65 years or less than45 years.\n* Subjects who have hearing problems\n* Patients have acute viral diseases, acute tuberculosis, mental disorders or those with pacemakers.\n* Diabetic, cardiac and renal patients.\n* Genetic disease\n* Patients who had any other breast cancer operations","45 Years",{"count":145,"type":23},[57],"The purpose of the study is to evaluate the therapeutic efficacy of exercise rehabilitation program on upper limb range and forward head posture post unilateral radical mastectomy.",[27],"2026-02-26",{"date":380,"type":37},"2026-03-03",{"date":382,"type":23},"2026-03-02",{"date":384,"type":23},"2026-06-15",{"name":386,"class":44},"Cairo University",{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":143,"enrollmentInfo":394,"targetDuration":4,"studyType":55,"phases":396,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":407,"leadSponsor":409,"locationsCount":81},"100625345","adding-amantadine-or-duloxetine-to-pregabalin-on-occurrence-of-post-mastectomy-pain-syndrome-100625345","NCT07421427","Adding Amantadine or Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain Syndrome","The Effect of Adding Amantadine or Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain Syndrome; Randomized Controlled Study","Inclusion Criteria:\n\n* Age from 18 to 65 years.\n* American society of anesthesiologists (ASA) Physical status II, III.\n* Body mass index (BMI): (20-40) kg\u002Fm2.\n* Type of surgery: patients undergoing modified radical mastectomy for breast cancer.\n\nExclusion Criteria:\n\n* Patient refusal.\n* Patients with Known sensitivity or contraindication to drug used in the study.\n* History of psychological disorders and\u002For chronic pain and drug abuse patients.\n* Previous administration of antidepressants, anticonvulsants, or opioids before surgery.\n* Severe respiratory or cardiac disorders.\n* Advanced liver or kidney disease.\n* Previous breast surgery",{"count":395,"type":23},150,[57],"This study aims to evaluate the additive effect of Amantadine or Duloxetine to Pregabalin on development of post mastectomy pain syndrome",[399,400,401,27,402],"Amantadine","Duloxetine","Pregabalin","Pain Syndrome","2026-02-21",{"date":405,"type":37},"2026-02-24",{"date":403,"type":37},{"date":408,"type":23},"2027-01-01",{"name":386,"class":44},{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":52,"minAge":418,"maxAge":143,"enrollmentInfo":419,"targetDuration":4,"studyType":55,"phases":421,"briefSummary":422,"conditions":423,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":81},"100536367","stellate-ganglion-block-for-prevention-of-post-mastectomy-depression-100536367","NCT06263907","Stellate Ganglion Block for Prevention of Post Mastectomy Depression","Preemptive Efficacy of Stellate Ganglion Block for Prevention of Post Mastectomy Depression","SGB","Inclusion Criteria:\n\n* Female patients\n* Age ranging from 18 to 65 years\n* American Society of Anesthesiologists (ASA) no more than II\n* Had unilateral cancer breast\n* Scheduled to do unilateral modified radical mastectomy\n\nExclusion Criteria:\n\n* Pregnant female\n* Existing Horner syndrome\n* Had any neuromuscular disease\n* Had allergy to local anesthetics\n* History of use of analgesics\n* Had any deformity or a previous surgery in the neck or ipsilateral arm or breast\n* Had any contraindication to the procedure (coagulation disorders, local infection, sepsis)\n* Had any contraindication to the sympathetic blockade (decompensate cardiopulmonary or hemodynamic disorders)\n* History of psychotic disorder including depression, bipolar disorder or personality disorder\n* Patient with Beck Depression Inventory (BDI) score more than 13","21 Years",{"count":420,"type":23},140,[57],"Complications after mastectomy include chronic pain and depression.",[27,424,425],"Pain, Acute","Pain, Chronic","2026-02-15",{"date":428,"type":37},"2026-02-17",{"date":430,"type":37},"2024-03-01",{"date":432,"type":23},"2028-12-30",{"name":434,"class":44},"Mansoura University",{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":55,"phases":445,"briefSummary":446,"conditions":447,"keywords":448,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":460},"100598469","a-prospective-study-of-video-assisted-exercise-program-for-the-breast-cancer-survivors-100598469","NCT07071896","A Prospective Study of Video-assisted Exercise Program for the Breast Cancer Survivors","Strong Survivors: A Prospective Study of Video-assisted Exercise Program for the Breast Cancer Survivors","StrongSurvivor","In order to be eligible to participate in this study, an individual must meet all the following criteria:\n\n1. Persons, aged 18+\n2. Undergone breast cancer surgery within the 4 weeks of being contacted for pre-screening\n\n   a. Acceptable surgery includes unilateral or bilateral mastectomy (Lymph node surgery is NOT required but is still acceptable)\n3. Own a computer or alternative device capable of real-time Zoom videoconferencing, including access to internet or cellular connectivity sufficient in broadband. This requires a screen of at least 7 inches (a cell phone is large enough for us to see the participant, but not for the participant to see us).\n4. Provision of signed and dated informed consent form\n5. Stated willingness to comply with all study procedures and availability for the duration of the study\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Have sustained a previous fall-related fracture within the last 2 years;\n2. have poorly controlled cardiovascular disease, pulmonary disease, or a debilitating musculoskeletal or neurological condition severely limiting function\u002Fability to perform the exercise program as determined by the breast surgeon at screening for trial enrollment\n3. experience vertigo or dizziness\u002Flight headedness observed at enrollment or during initial occupational therapy evaluation.\n4. are on multiple benzodiazepine or neuroleptic medications.\n5. Pregnant or trying to become pregnant\n\n   \\-",{"count":444,"type":23},15,[57],"The investigators cancer rehabilitation\u002Frecovery program, Strong Survivor, has been designed to be delivered digitally, and while there are many such programs currently available on the internet, especially in the time of COVID-19, the novel feature of this program is the delivery of semi-individualized instruction in real time within a small group setting. The program was designed with physician input and by exercise physiologists and a Doctor of Physical Therapy candidate, all with extensive training in both group and individualized exercise for geriatric and cancer survivor populations. Strong Survivor is 16-week iterative curricular program with three core components: aerobic fitness, balance and mobility, and muscular strength and power. Classes will be held twice per week. The first 4 classes will be deployed in a small class of up to 5 people (first 2 weeks), then one class per week with the small class and one class per week is with a larger class of up to 15 people (weeks 3 and 4). The program is then continued for 12 additional weeks in a larger class using principles and exercises specifically trained during the small group classes.\n\nAll the exercises offered over the course of the intervention are appropriate for the target population and are standardized so all participants receive the same basic instruction, but level of difficulty is scaled to participant experience, capability, and musculoskeletal limitations.\n\nParticipants will need to have a minimal adequate space and technology to accommodate this instructional method. Specifically, they will require an internet connected device with a camera that is at least 7 inches square. (tablet size or larger).\n\nAdditionally, participants' will need to have adequate space to both set up a computer\u002Fcamera and move around. The minimal acceptable space for this is 6+ feet with an unobstructed view (from a table for instance) of a 2 x 2 open space.\n\nAll study participants will complete a clinic visit before they join the classes and after the last class to evaluate cardiorespiratory fitness, strength, balance and posture and answer questionnaires about quality of life and system usability.",[27],[449,450],"Exercise, Mastectomy","rehabilitation","2026-02-05",{"date":453,"type":37},"2026-02-10",{"date":455,"type":37},"2025-01-10",{"date":457,"type":23},"2026-12-23",{"name":459,"class":44},"University of California, San Diego",2,{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":55,"phases":471,"briefSummary":472,"conditions":473,"keywords":482,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":460},"100620812","finding-sentinel-lymph-nodes-during-mastectomy-using-indocyanine-green-inigma-study-100620812","NCT07362485","Finding Sentinel Lymph Nodes During Mastectomy Using Indocyanine Green (INIGMA Study)","Indocyanine Green Guided Identification of Sentinel Lymph Nodes Via Mastectomy Incision in Breast Cancer Patients (INIGMA Study)","INIGMA","Inclusion Criteria:\n\n* Clinically node-negative, DCIS, invasive T1- T3 breast cancer confirmed by biopsy.\n* Preoperative axillary ultrasound to confirm clinical node-negative status.\n* Indication (or preference) for mastectomy and simultaneous SLN procedure.\n* Written informed consent according to ICH\u002FGCP and national regulations.\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years old\n* Breast conserving surgery\n* Direct reconstruction (with autologous tissue or implant)\n* Known allergy for indocyanine green (ICG) or radioisotope technetium (99mTc), intravenous contrast or iodine\n* Other concurrent solid tumour\n* Hyperthyroidism or thyroid cancer\n* Pregnancy or breast feeding\n* Psychological, familial, sociological or geographical factors that could potentially hamper compliance with the study protocol",{"count":470,"type":23},90,[57],"This pilot study evaluates the diagnostic value of indocyanine green (ICG) fluorescence for sentinel lymph node biopsy (SLNB) performed through the mastectomy incision in breast cancer patients.\n\nWomen with clinically node-negative, invasive T1-T3 breast cancer undergoing mastectomy with SLNB at St. Antonius or Isala Hospital will be included. All patients receive standard 99mTc injection preoperatively, followed by 5 mg (2mL) ICG injection after anesthesia. The axilla will be explored for fluorescent lymph nodes via the mastectomy incision, avoiding a separate axillary incision.\n\nPrimary outcome: ICG detection rate for SLN identification via the mastectomy incision.\n\nSecondary outcomes: Comparison with 99mTc detection, number of nodes identified, concordance between methods, pathology differences, detection time, and complications.\n\nICG is safe, non-ionizing, and causes no extra discomfort or visits. Risks and burden are minimal.",[149,474,475,476,477,478,479,480,481,27],"Sentinel Lymph Node Biopsy (SLNB)","Sentinel Lymph Node Detection","Sentinel Lymph Node","Lymphatic Metastasis","Fluorescence Imaging","Indocyanine Green (ICG)","Radioisotopes","Lymph Node Mapping",[276,483,484,27,485,486,487,488,489],"Sentinel lymph node biopsy","Indocyanine green","Fluorescence imaging","Lymph node mapping","Surgical oncology","Techetium nanocolloïd","Radioisotope","2026-01-15",{"date":492,"type":37},"2026-01-23",{"date":494,"type":37},"2022-08-22",{"date":496,"type":23},"2026-06",{"name":498,"class":44},"Isabelle Henskens",{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":505,"eligibilityCriteria":506,"healthyVolunteers":12,"sex":52,"minAge":113,"maxAge":507,"enrollmentInfo":508,"targetDuration":4,"studyType":55,"phases":510,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":81},"100450537","a-study-to-reduce-persistent-post-mastectomy-pain-using-opioid-free-anesthesia-100450537","NCT05146778","A Study to Reduce Persistent Post-mastectomy Pain Using Opioid-free Anesthesia","A Single-blinded Randomized-controlled Study to Reduce Persistent Post-mastectomy Pain Using Multimodal Opioid-free Anesthesia","RELIEF","Inclusion Criteria:\n\n* All of patients will undergo mastectomy with or without immediate breast reconstruction.\n\nExclusion Criteria:\n\n* Previous history of breast surgery\n* Allergy to drug\n* Other cancer history\n* Underlying psychologic disorder\n* Patients with chronic pain requiring pain killers\n* Baseline SpO2 \\\u003C95%\n* Left ventricular EF \\\u003C40%\n* Bradycardia as HR \\\u003C50 bpm\n* BMI \\>35kg\u002Fm2\n* Pregnant woman","80 Years",{"count":509,"type":23},230,[57],"In 230 patients undergoing mastectomy, the investigators will compare opioid-free anesthesia (OFA) versus conventional opioid-based anesthesia in terms of chronic pain. The enrolled patients will be randomly assigned into two groups with 1:1 ratio. Chronic pain will be evaluated at 1 year after mastectomy based on the Breast Cancer Pain Questionnaire (BCPQ). Baseline pain sensitivity test and psychologic evaluation will be done before operation.",[149,27,425,513],"Pain, Post Operative","2025-11-18",{"date":516,"type":37},"2025-11-21",{"date":518,"type":37},"2021-12-16",{"date":520,"type":23},"2027-10-31",{"name":522,"class":44},"Gangnam Severance Hospital",{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":530,"enrollmentInfo":531,"targetDuration":4,"studyType":55,"phases":533,"briefSummary":534,"conditions":535,"keywords":540,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":460},"100477248","impact-of-erector-spinae-plane-block-on-chronic-postsurgical-pain-in-breast-cancer-patients-100477248","NCT05494502","Impact of Erector Spinae Plane Block on Chronic Postsurgical Pain in Breast Cancer Patients","Impact of Erector Spinae Plane Block With Adjuvant Dexmedetomidine on Chronic Postsurgical Pain in Breast Cancer Patients: a Two-center Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age of 18 years or over, but less than 85 years;\n2. Scheduled to undergo mastectomy for primary unilateral breast cancer.\n\nExclusion Criteria:\n\n1. Previous breast cancer surgery with an incision of \\>2 cm;\n2. Chronic opioid dependence or long-term intake of analgesic medicines (\\>3 months);\n3. Any contraindication to erector spinae plane block, including intrathoracic infection, infection at the puncture site, cancer invasion of the puncture site, severe spinal deformity, history of spinal surgery, and severe coagulopathy;\n4. Inability to communicate in the preoperative period because of profound dementia, deafness, language barriers, or end-stage disease;\n5. History of malignant tumor in other organs, or a current combination of malignant tumor of other organs;\n6. History of coronary heart disease (diagnosed coronary stenosis, previous myocardial infarction, previous percutaneous coronary intervention or coronary artery bypass grafting); preoperative hepatic or renal impairment (alanine transaminase and\u002For aspartate transaminase ≥2 times of upper limit of normal, or serum creatinine\\>133 µmol\u002FL); history of peptic ulcer or hemorrhage; ASA classification IV or above;\n7. Allergy to ropivacaine.","85 Years",{"count":532,"type":23},1206,[57],"Chronic postsurgical pain (CPSP) has an incidence of 46% in patients after breast cancer surgery, which seriously affects patients' physiological and psychological function, as well as quality of life. Acute pain is an independent risk factor for persistent pain after surgery. Erector spinae plane block (ESPB) provided excellent perioperative analgesia in patients undergoing breast surgery. Dexmedetomidine as an adjuvant of local anesthetics prolongs the duration of peripheral nerve block and decreases the requirements of postoperative analgesia. The investigators hypothesize that, for breast cancer patients undergoing mastectomy, ESPB (with a combination of 0.5% ropivacaine 35 ml and dexmedetomidine 1 microgram\u002Fkg) can reduce the occurrence of CPSP. The purpose of this randomized controlled trial is to investigate the impact of ESPB with adjuvant dexmedetomidine on the incidence of CPSP in breast cancer patients after mastectomy. We will also observe the impact of ESPB on long-term survival in these patients.",[536,27,312,537,538,210,539],"Breast Neoplasms","Dexmedetomidine","Pain, Postoperative","Prognosis",[276,27,541,537,286,542,543],"Erector spinae plane block","Chronic postsurgical pain","Long-term prognosis","2025-07-29",{"date":546,"type":37},"2025-07-31",{"date":548,"type":37},"2023-05-23",{"date":550,"type":23},"2027-07",{"name":552,"class":44},"Peking University First Hospital",{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":557,"acronym":4,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":52,"minAge":559,"maxAge":560,"enrollmentInfo":561,"targetDuration":4,"studyType":55,"phases":562,"briefSummary":563,"conditions":564,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":574,"locationsCount":81},"100594781","effect-of-kinetic-control-exercise-on-shoulder-dysfunction-post-mastectomy-100594781","NCT07023913","Effect of Kinetic Control Exercise on Shoulder Dysfunction Post Mastectomy","Inclusion Criteria:\n\nThe subject selection will be according to the following criteria:\n\n* Age from 40 to 50 years.\n* All patients have no diabetes or blood problems.\n* All patients enrolled to the study will have their informed consent.\n\nExclusion Criteria:\n\nThe potential participants will be excluded if they meet one of the following criteria:\n\n* Age less than 40 or more 50 years.\n* Diabetes mellitus.\n* Subjects with lymphedema\n* Subjects suffering from active malignant tumors.\n* Subjects treated with skin graft.\n* Subjects with Mental illness.\n* Subjects with skin diseases\n* Subjects with any previous cause for shoulder dysfunction","40 Years","50 Years",{"count":145,"type":23},[57],"The purpose of this study is to evaluate the effect of kinetic control exercises on shoulder dysfunction in post-mastectomy.",[565,566,567,27],"Kinetic Control","Dysfunction","Shoulder","2025-06-14",{"date":570,"type":37},"2025-06-17",{"date":572,"type":23},"2025-06-15",{"date":321,"type":23},{"name":386,"class":44},{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":582,"targetDuration":4,"studyType":55,"phases":584,"briefSummary":585,"conditions":586,"keywords":597,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":81},"100593584","impact-of-nipple-reconstruction-in-mastectomized-patients-using-cross-linked-hyaluronic-acid-injection-100593584","NCT07008339","Impact of Nipple Reconstruction in Mastectomized Patients Using Cross-Linked Hyaluronic Acid Injection.","RECHIAL","* Quantitative Phase\n* Inclusion Criteria:\n\nWomen over 18 years of age, or with parental or legal guardian consent.\n\nAt least one of the following criteria:\n\nWomen undergoing their first nipple-areola complex (NAC) reconstruction through micropigmentation and\u002For:\n\nNo previous neo-nipple surgery, either unilaterally or bilaterally.\n\nSurgical reconstruction of the areola.\n\nSurgical reconstruction of the NAC with subsequent retraction of the neo-nipple.\n\nMore than 6 months since their last surgery.\n\n\\- Exclusion Criteria:\n\nAllergy to hyaluronic acid.\n\nPoor tolerance to needle injections.\n\nWithdrawal Criteria:\n\nParticipant's voluntary decision.\n\nComplications associated with the technique (allergy, hematoma, etc.).\n\nClinical deterioration preventing the woman from continuing in the study.\n\n\\- Qualitative Phase\n\nParticipant Profile Characteristics: For the qualitative phase, women who have received NAC reconstruction with HA will be invited to participate, following the maximum variation criterion. To ensure the inclusion of participants with diverse characteristics and capture a wide range of perspectives and experiences on the phenomenon under study, women of varying ages, with different breast cancer diagnoses, and histories of various oncological, surgical, and therapeutic treatments will be selected.",{"count":583,"type":23},138,[57],"This study evaluates the impact of hyaluronic acid (HA) injection for nipple projection following mastectomy, as a complement to areola micropigmentation. While micropigmentation is standard in nipple-areola complex (NAC) reconstruction, HA use remains novel, with limited data on psychosocial, sexual, and aesthetic outcomes.\n\nA sequential explanatory mixed-methods design will be used. In Phase 1, a randomized controlled trial will compare two groups: one receiving NAC micropigmentation alone (control) and the other receiving micropigmentation plus HA-based nipple projection (intervention). A total of 138 participants will be recruited at the Areolar Micropigmentation Unit of Germans Trias i Pujol University Hospital (Barcelona) over 36 months. Outcomes will include psychosocial and sexual well-being, satisfaction with breast and nipple appearance, and nipple projection, measured using the Spanish BREAST-Q, a custom satisfaction tool, and calipers.\n\nPhase 2 will involve a qualitative phenomenological study using semi-structured interviews with a purposive sample from the intervention group. Thematic analysis will explore body image, emotional and social well-being, and overall satisfaction, using NVivo software.\n\nThis is the first study assessing HA nipple reconstruction by advanced practice nurses using validated patient-reported outcomes. While the BREAST-Q is appropriate, it may not fully capture emotional nuances, justifying qualitative exploration. HA durability is estimated at 6-9 months, but residual volume and satisfaction over time remain underexplored. HA's aesthetic footprint may allow reduced dosages in future applications.\n\nThis minimally invasive technique may reduce the need for surgical nipple reconstruction. Conducting the procedure in a nurse-led setting is novel and may enhance patient-centered care and the role of nursing in post-mastectomy recovery.\n\nThe study complies with the Declaration of Helsinki and Spanish biomedical regulations. Ethical approval was obtained. Participants will provide informed consent, and data will be anonymized and securely stored.",[536,27,93,587,588,589,590,591,592,593,594,595,94,596],"Nipple Disorder","Tattooing","Hyaluronic Acid","Dermal Fillers","Reconstructive Surgical Procedures","Quality of Life","Self Concept","Body Image","Patient Satisfaction","Nipple Reconstruction",[149,27,94,598,596,599,589,590,600,588,594,592,601,602,595,603],"Nipple-Areola Complex Reconstruction","Areola Reconstruction","Micropigmentation","Postmastectomy Reconstruction","Cross-linked Hyaluronic Acid","Breast Cancer Survivors","2025-06-04",{"date":606,"type":37},"2025-06-06",{"date":608,"type":37},"2023-06-02",{"date":610,"type":23},"2029-07-02",{"name":612,"class":44},"Germans Trias i Pujol Hospital",{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":4,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":175,"enrollmentInfo":620,"targetDuration":4,"studyType":55,"phases":621,"briefSummary":622,"conditions":623,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":632,"leadSponsor":634,"locationsCount":81},"100586074","dexmedetomidine-versus-lidocaine-infusions-as-adjuvants-to-general-anesthesia-for-chronic-pain-management-after-mastectomy-100586074","NCT06910644","Dexmedetomidine Versus Lidocaine Infusions as Adjuvants to General Anesthesia for Chronic Pain Management After Mastectomy","Dexmedetomidine Versus Lidocaine Infusions as Adjuvants to General Anesthesia for Chronic Pain Management After Mastectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age from 18 to 75 years.\n* American Society of Anesthesiologists (ASA) physical status II.\n* Scheduled for mastectomy with axillary dissection (either modified radical mastectomy with or without latissimus dorsi flap or conservative breast surgery) due to breast cancer.\n\nExclusion Criteria:\n\n* Patient refusal.\n* Known allergy to any of the study drugs.\n* Those with hepatic or renal insufficiency.\n* Patients who are running regularly on B blockers.\n* α2 adrenergic agonists and sedatives.\n* Psychoactive medications.",{"count":470,"type":23},[57],"This study aims to compare dexmedetomidine and lidocaine infusions as adjuvants to general anesthesia for chronic pain management after mastectomy.",[537,624,625,626,627,210,27],"Lidocaine","Infusion","Adjuvants","General Anesthesia","2025-04-05",{"date":630,"type":37},"2025-04-08",{"date":628,"type":37},{"date":633,"type":23},"2025-12-01",{"name":386,"class":44},{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":640,"acronym":4,"eligibilityCriteria":641,"healthyVolunteers":12,"sex":18,"minAge":113,"maxAge":4,"enrollmentInfo":642,"targetDuration":644,"studyType":24,"phases":4,"briefSummary":645,"conditions":646,"keywords":648,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":650,"lastUpdatePostDateStruct":651,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":657,"locationsCount":81},"100554937","preoperative-vs-pathologic-size-in-breast-cancer-a-prospective-study-100554937","NCT06505577","Preoperative vs. Pathologic Size in Breast Cancer: A Prospective Study","Concordance Between Preoperative Assessments and Pathologic Size Measurements in Breast Cancer: a Prospective Observational Study","Inclusion Criteria:\n\nAdult patients (≥ 19 years old) diagnosed with breast cancer (invasive and in situ).\n\nPatients scheduled for surgical resection of the tumor Availability of both preoperative tumor size assessments and pathologic measurements post-surgery\n\nExclusion Criteria:\n\nPatients with recurrent breast cancer Inflammatory breast cancer Patients who did not undergo surgery Patients whose preoperative tumor size data is not available or deficient for analyzing",{"count":643,"type":23},600,"1 Year","Breast cancer, the most prevalent malignancy among women globally, is increasing in incidence. While non-metastatic breast cancer requires surgery, determining the optimal extent of resection remains challenging. Inadequate resection margins necessitate reoperation, leading to increased psychological stress, costs, and potentially compromised cosmetic outcomes and prognosis.\n\nAccurate preoperative assessment of resection extent is crucial and involves various factors, including imaging studies, physical examinations, tumor molecular subtypes, and intraductal carcinoma components. This prospective observational study aims to identify and integrate multiple predictive factors to enhance surgical planning and minimize reoperation rates in breast cancer patients.",[27,647],"Breast Neoplasm Malignant Primary",[276,27,649],"Ductal carcinoma in situ","2025-04-03",{"date":652,"type":37},"2025-04-06",{"date":654,"type":37},"2024-08-01",{"date":656,"type":23},"2027-08-30",{"name":658,"class":44},"Incheon St.Mary's Hospital",{"id":660,"slug":661,"hasResults":12,"nctId":662,"briefTitle":663,"officialTitle":664,"acronym":665,"eligibilityCriteria":666,"healthyVolunteers":112,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":667,"targetDuration":4,"studyType":55,"phases":669,"briefSummary":670,"conditions":671,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":674,"lastUpdatePostDateStruct":675,"startDateStruct":677,"completionDateStruct":679,"leadSponsor":681,"locationsCount":81},"100508359","seroma-of-the-mammary-gland-100508359","NCT05899387","Seroma of the Mammary Gland","Prospective, International, Multicenter Minimal Interventional Study to Detect Possible Markers for Prediction of Seroma Development and Risk Assessment of a Breast Seroma After Mastectomy with or Without Implant-based Breast Reconstruction","SerMa","Inclusion criteria study group and control group 1:\n\n* Written informed consent\n* Age ≥ 18 years\n* all stages of DCIS or primary breast cancer (T1-T4, N0 or N+, M0) including all histopathological subtypes (ER\u002FPR positive, ER positive\u002FPR negative, Her-2\u002Fneu positive and triple negative)\n* Surgical procedure planned including ablatio or subcutaneous mastectomy with implant or expander insertion\n\nInclusion criteria control group 2 and 3:\n\n* Written informed consent\n* Age ≥ 18 years\n* Surgical procedure planned with implant or expander insertion with or without subcutaneous mastectomy\n\nExclusion criteria:\n\n* Age \\\u003C18 years\n* Male sex\n* Breast cancer patients planned for breast conserving therapy\n* Recurrent breast cancer disease\n* History of breast surgery\n* Diagnosis of LCIS only\n* Pregnancy at time of diagnosis\n* Patients with a known immunodeficiency",{"count":668,"type":23},2000,[57],"The study is designed as international, prospective, minimal interventional study in cooperation with EUBREAST e.V. (European Breast Cancer Research Association of Surgical Trialists). Furthermore, it is planned to initiate a registry for postoperative breast seromas.",[672,149,27,673],"Seroma","Breast Implant; Complications","2025-02-25",{"date":676,"type":37},"2025-02-28",{"date":678,"type":37},"2024-04-01",{"date":680,"type":23},"2027-07-01",{"name":682,"class":44},"University Hospital Augsburg"]